Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Genitourinary 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 120Carboplatin 114Pemetrexed 74Cisplatin 71Nivolumab 68Paclitaxel 58Docetaxel 56Radiotherapy 41Erlotinib Hydrochloride 41Gemcitabine 35Etoposide 34atezolizumab 30osimertinib 29Cetuximab 27Ipilimumab 25Bevacizumab 25Radiosurgery 22durvalumab 21Cyclophosphamide 20Drug Therapy 18130-nm albumin-bound paclitaxel 17avelumab 14Taxes 14Gefitinib 14Albumin-Bound Paclitaxel 14Irinotecan 13Injections 13fludarabine 11Radiation 11cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Nelfinavir × Thoracic × Clear all
NCT00589056 2020-04-24

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Abramson Cancer Center at Penn Medicine

Phase 1/2 Completed
55 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01447589 2016-06-23

NelfLung

Oxford University Hospitals NHS Trust

Phase 1/2 Withdrawn
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡